Comparison · NCT01799993-2ec451fa
Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Emergence of Resistance Among Pathogens
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Emergence of Resistance Among Pathogens. Trial comparisons, record NCT01799993-2ec451fa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01799993-2ec451fa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0699 | 0.0413 | 0.116 | wilson | |
| Risk in group 2 | 0.0876 | 0.0554 | 0.136 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0177 | -0.0738 | 0.0384 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.798 | 0.399 | 1.6 | log | |
| Odds ratio, group 1 over group 2 | 0.782 | 0.369 | 1.66 | log | |
| Number needed to treat, for one fewer participant with the outcome on Amikacin Inhale (BAY41-6551) than on Placebo | 56.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Amikacin Inhale (BAY41-6551) | Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10. | 13 | 186 | OG000 |
| Group 2 | Placebo | Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10. | 17 | 194 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Participants With Emergence of Resistance Among Pathogens
- Description
Resistance to amikacin was determined for the bacterial isolates by using a standardized microbiology laboratory test that generates a minimum inhibitory concentration (MIC) for amikacin and bacterial isolate. The same microbiology resistance standard was used for all bacteria tested against amikacin. Resistant bacteria have a MIC value of 64 μg/mL or greater. Percentages of resistance were calculated based on the percentage of participants infected with any treatment-emergent pathogens resistant to amikacin. If a participant had a more than one occurrence of a specific pathogen during pre-treatment period, the worst case of testing was used.
- Time frame
- Up to 28-32 days after start of study treatment
- Population
- mITT population participants with pathogen susceptible to amikacin in pre-treatment period
Source ClinicalTrials.gov
Trial
- Title
- Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
- NCT number
- NCT01799993
- Phases
- PHASE3
- Conditions
- Pneumonia, Bacterial
- Interventions
- Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2018-06-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01799993?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01799993-2ec451fa